h8F4-BiTE

N/A

Report date: 2026/03/19 16:53:38

Base Information

Drug Nameh8F4-BiTE
Drug Alias Nameanti-CD3/anti-PR1/HLA-A2 bispecific T-cell engager (MD Anderson Cancer Center)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsHistocompatibility antigens class II modulators
TargetsHistocompatibility antigens class IIT cell surface glycoprotein CD3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A